Bank of New York Mellon Corp trimmed its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,516,919 shares of the medical research company’s stock after selling 30,079 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.88% of Thermo Fisher Scientific worth $665,402,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TMO. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 2.4% during the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock worth $4,640,970,000 after purchasing an additional 629,093 shares in the last quarter. BlackRock Inc. increased its position in shares of Thermo Fisher Scientific by 1.6% during the second quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock worth $4,074,828,000 after purchasing an additional 366,584 shares in the last quarter. Capital Research Global Investors increased its position in shares of Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after purchasing an additional 3,973,136 shares in the last quarter. State Street Corp increased its position in shares of Thermo Fisher Scientific by 1.0% during the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after purchasing an additional 164,367 shares in the last quarter. Finally, Capital World Investors increased its position in shares of Thermo Fisher Scientific by 6.1% during the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after purchasing an additional 671,637 shares in the last quarter. 86.16% of the stock is owned by institutional investors and hedge funds.

In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.49% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down $10.17 during midday trading on Tuesday, hitting $182.03. The stock had a trading volume of 3,926,700 shares, compared to its average volume of 1,555,471. The stock has a market cap of $77,071.31, a PE ratio of 21.12, a PEG ratio of 1.76 and a beta of 1.06. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a fifty-two week low of $139.88 and a fifty-two week high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.03 EPS. analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.33%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

Several brokerages recently commented on TMO. Leerink Swann reiterated an “outperform” rating and set a $200.00 price target (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target for the company in a research report on Tuesday, October 31st. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Jefferies Group restated a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Goldman Sachs Group began coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $205.21.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/05/thermo-fisher-scientific-inc-tmo-shares-sold-by-bank-of-new-york-mellon-corp.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.